-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Track & Monitor
PharmSource – M&A in the Contract Manufacturing Industry: Implications and Outlook – 2018 Edition
This report is the 2nd edition of our analysis of Mergers and Acquisitions in the contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2019 PharmSource Edition
This report is the 9th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals
The pharmaceutical and healthcare industry reported an increase in the number of deals and a decrease in deal values in December 2016. The industry reported 324 deals worth USD27.9 billion in December 2016, compared to 313 deals worth USD33.9 billion in November 2016. The oncology therapeutics market remained at the top in deal activity in December 2016 with 108 deals. In second place, central nervous system therapeutics market reported 61 deals. Licensing agreements in pharmaceutical and healthcare industry registered an...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2016
The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q4 2016 with 986 deals worth USD81.7 billion, as compared 1,194 worth USD85.9 billion in Q4 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q4 2016, when compared to 1,009 deals worth USD112.6 billion in Q3 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD1 billion in Q4 2016,...